FDA clears Editas to test gene-editing drug in humans
The FDA has signed off on Cambridge startup Editas Medicine's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans.
Editas (Nasdaq: EDIT) said that the FDA approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments of DNA.
The study, which Editas…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Blindness | Clinical Trials | Genetics | Health Management | Opthalmology | Pharmaceuticals | Study